LACHEN, Schweiz--(BUSINESS WIRE)--Octapharma meldet die Veröffentlichung neuer Daten, aus denen hervorgeht, dass das Fibrinogenkonzentrat fibryga® bei Patienten, die während einer Herzoperation schwere Blutungen erleiden, eine wirksame Alternative zum Kryopräzipitat darstellt. Die Daten wurden vor kurzem im Journal of the American Medical Association (JAMA) veröffentlicht.1 Übermäßige Blutungen stellen während einer Operation ein großes Problem dar. Ein übermäßiger Blutverlust bzw. ein erhöhter
Thu Oct 31, 2019 23:26
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019. Third-quarter 2019 net sales were $560.6 million, an increase of 2.8 percent compared to $545.1 million reported for the third quarter of 2018. On a currency-neutral basis, quarterly sales increased 4.5 percent compared to the same period in 2018, reflecting
Thu Oct 31, 2019 22:15
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals Announces Appointment of Kleem Chaudhary as Chief Business Officer
Thu Oct 31, 2019 22:15
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to report its third-quarter 2019 financial results on Thursday, November 7, 2019, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 9845948. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” s
Thu Oct 31, 2019 22:15
Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics announced results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided its financial outlook for fiscal 2020.
Thu Oct 31, 2019 22:05
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that new data from across the companies’ inflammatory disease research and development program will be presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting in Atlanta from November 8-13. The companies will present 20 abstracts at this year’s meeting, including key data...
Thu Oct 31, 2019 22:01
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference in November: Credit Suisse Healthcare Conference Location: Scottsdale, AZ Date: Tuesday, November 12, 2019 Presentation: 8:35 a.m. MT (10:35 a.m. ET) Speakers: Dr. August Troendle, President & Chief Executive Officer, and Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations A live webcast of the present
Thu Oct 31, 2019 22:00
LACHEN, Suíça--(BUSINESS WIRE)--A Octapharma anunciou a publicação de novos dados que demonstram que o concentrado de fibrinogênio, fibryga® , é uma alternativa eficaz ao crioprecipitado em pacientes com sangramento grave durante cirurgia cardíaca. Os dados foram publicados recentemente no Journal of the American Medical Association (JAMA).1 O sangramento excessivo é uma grande preocupação durante a cirurgia e a perda excessiva de sangue e/ou o consumo de fatores de coagulação podem levar à def
Thu Oct 31, 2019 21:35
LACHEN, Suisse--(BUSINESS WIRE)--Octapharma a annoncé la publication de nouvelles données démontrant que le concentré en fibrinogène fibryga® constitue une alternative efficace au cryoprécipité pour les patients victimes de saignements graves au cours d'une chirurgie cardiaque. Ces données ont récemment été publiées dans le Journal of the American Medical Association (JAMA).1 Les saignements excessifs constituent une préoccupation majeure au cours des interventions chirurgicales, et une perte d
Thu Oct 31, 2019 20:42
SALT LAKE CITY--(BUSINESS WIRE)-- #QTprolongation--SignPath Pharma, Inc. Announces an Out-license Agreement of Its CorreQT(TM) Technology for Mitigation of QT Prolongation with Rain Therapeutics Inc.
Thu Oct 31, 2019 20:20
LACHEN, Suiza--(BUSINESS WIRE)--Octapharma ha anunciado la publicación de nuevos datos que demuestran que el concentrado de fibrinógeno fibryga® es una alternativa eficaz al crioprecipitado para pacientes con sangrado grave durante la cirugía cardíaca. Los datos han sido publicados recientemente en el Journal of the American Medical Association (JAMA).1 El sangrado excesivo es una preocupación importante durante la cirugía y la pérdida excesiva de sangre o el consumo del factor de coagulación p
Thu Oct 31, 2019 19:37
Major Depressive Disorder (MDD) Research Study Are you currently struggling with depression? Have you been unable to find relief with standard antidepressant medication? If so, you may be eligible to participate in a clinical trial. The purpose of this study is to evaluate the effectiveness of 3 FDA approved depression treatments. Compensation and reimbursement for study related travel may be available. For more information about the study: Visit: https://clinicaltrials.gov/ct2/show/NCT02977299...
Thu Oct 31, 2019 00:00
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals presents at North American Cystic Fibrosis Conference on RNAi candidate ARO-ENaC
Thu Oct 31, 2019 18:15
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies through the use of Invenra’s B-BodyTM technology platform. The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs. “The expanded collaboration speaks to the strength and
Thu Oct 31, 2019 18:00
STRIDES-X-Ray StudyClinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication. Qualified study participants will receive study related care at no cost. See if you or a loved one qualify! Participation Requirements You or a Loved One May Qualify If You: Are between 40-80...
Thu Oct 31, 2019 00:00
STRIDES-X-Ray StudyClinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication. Qualified study participants will receive study related care at no cost. See if you or a loved one qualify! Participation Requirements You or a Loved One May Qualify If You: Are between 40-80...
Thu Oct 31, 2019 00:00
STRIDES-X-Ray StudyClinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication. Qualified study participants will receive study related care at no cost. See if you or a loved one qualify! Participation Requirements You or a Loved One May Qualify If You: Are between 40-80...
Thu Oct 31, 2019 00:00
STRIDES-X-Ray StudyClinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication. Qualified study participants will receive study related care at no cost. See if you or a loved one qualify! Participation Requirements You or a Loved One May Qualify If You: Are between 40-80...
Thu Oct 31, 2019 00:00
STRIDES-X-Ray StudyClinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication. Qualified study participants will receive study related care at no cost. See if you or a loved one qualify! Participation Requirements You or a Loved One May Qualify If You: Are between 40-80...
Thu Oct 31, 2019 00:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου